诺诚健华2025年第一季度业绩报告显示,公司拥有77.8亿元现金及相关账户结余,营收同比增长129.9%至3.8亿元,实现净利润0.14亿元。核心产品奥布替尼销售收入同比增长89.2%至3.1亿元,成为增长引擎。奥布替尼新增适应症获批并入选CSCO指南,商业化与对外合作双轮驱动助力营收提升。研发方面,坦昔妥单抗上市申请获优先审评,zurletrectinib和mesutoclax分别获得优先审评和...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.